Clinical trial
Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's…
NCT00005969 · M.D. Anderson Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00005969 |
|---|---|
| Title | Liposomal Tretinoin in Treating Patients With Recurrent or Refractory Hodgkin's Disease |
| Official title | Phase II Study of ATRAGEN (Liposomal Tretinoin) in Patients With Relapsed or Refractory Hodgkin's Disease |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Chemotherapy, Tretinoin Liposome |
| Enrollment | 0 |
| Start date | Sep 1, 1999 |
| Primary completion | Jan 1, 2001 |
| First posted | Apr 28, 2004 |
| Last update posted | Feb 20, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: